Study of a vaccine for the prevention of Respiratory Syncytial Virus
GSK RSV - 012
Overview / Background
Our practice is participating in a clinical trial following on from a clinical trial (RSV OA=ADJ-006) that we participated in for a new vaccine to prevent Respiratory Syncytial Virus (RSV) infection.
To participate in this clinical study you will need to have received either the placebo vaccine or just one injection of the RSV vaccine in RSV OA=ADJ-006.
This study is being done to test if the RSV vaccine that you received in the previous study continues to provide you with defence against the virus after a single injection, if an extra dose (called revaccination) can help make more antibodies against the virus and when is the best time to give another dose of the vaccine to give the best number of antibodies.
This study will also give people the opportunity to receive the vaccine if they received the placebo vaccine in the previous study.
Process
Outcomes
Additional Information
What is RSV?
Respiratory Syncytial Virus (RSV) is a highly contagious virus that can impact everyone and in mild cases presents like a common cold. However, RSV can also cause more serious respiratory illness, mainly in older adults and in young infants. Like influenza, RSV infection is common during the winter months in temperate climates.
What are the symptoms?
If you have an RSV infection, you may have one or more of the following symptoms:
- Cough
- Stuffy or runny nose
- Sore throat
- Breathing difficulty
- Fever
RSV can lead to more serious complications, such as pneumonia in older adults and bronchiolitis in infants. RSV may also worsen some existing conditions, such as chronic respiratory or heart diseases.
Treatment and prevention of RSV
There are currently two vaccines that have been approved in the UK for the protection of adults aged 60 and over against RSV, one of which is GSK’s Arexvy®
Recruitment
To participate in this clinical study you will need to have received either the placebo vaccine or just one injection of the RSV vaccine in RSV OA=ADJ-006.
Get Involved
This study has now concluded.
Would you like to participate in an upcoming study?
Click below to send us your details and a member of the team will be in touch.
